세계의 Pharma 4.0 시장 : 규모, 점유율, 동향 분석-유형별, 용도별, 최종 용도별, 기술별, 지역별, 전망 및 예측(2024-2031년)

The Global Pharma 4.0 Market size is expected to reach $36.4 billion by 2031, rising at a market growth of 18.5% CAGR during the forecast period.

Telemedicine and remote healthcare solutions have grown significantly in recent years due to the increasing demand for accessible healthcare services. As more patients seek medical consultations and treatments remotely, the pharmaceutical industry must adapt by adopting connected systems that ensure timely drug manufacturing and delivery. According to the World Bank, the global telemedicine industry was expected to grow at an estimated 15% a year before the pandemic by mid-decade. Thus, the Healthcare Providers segment captures $1.8 Billion revenue in 2023.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In July, 2024, Dassault Systemes SE partnered with Mistral AI, a French AI company, to bring advanced AI, including large language models (LLMs), to industries. This partnership offers LLMaaS through Dassault's secure OUTSCALE infrastructure, empowering customers with AI-powered virtual twin experiences for industrial transformation, sustainability, and innovation, while preserving security and intellectual property. Moreover, In February, 2024, IBM Corporation teamed up with Wipro, an Indian IT company, to launch an Enterprise AI-Ready Platform, leveraging IBM's watsonx AI and data tools to offer clients customizable, integrated AI environments. This new service would enhance AI adoption with improved automation, governance, and flexibility for various industry applications.

COVID 19 Impact Analysis

The pandemic eventually accelerated the adoption of this 4.0 technologies as companies recognized the need for resilient, agile, and efficient manufacturing systems. The pressure to develop and produce COVID-19 vaccines quickly demonstrated the value of AI, automation, and IoT for optimizing production processes. These 4.0 tools, like predictive analytics and remote monitoring, gained widespread attention as pharmaceutical firms sought to minimize disruptions and prepare for future crises. The long-term effect of the pandemic has been a stronger push toward digital transformation in the pharmaceutical industry. Thus, the pandemic had an overall negative impact on the market.

Market Growth Factors

The ability to process vast amounts of data in real-time allows pharmaceutical companies to adopt predictive maintenance strategies, where AI-driven analytics can detect potential equipment failures long before they happen. This capability minimizes downtime, improves overall productivity, and reduces operational costs. In order to identify subtle changes in performance that may indicate a problem, AI systems perpetually monitor machinery by utilizing historical data and machine learning algorithms. Hence, all these factors will aid in the growth of the market.

Digital transformation and cloud technologies are pivotal in advancing the pharmaceutical industry under the 4.0 framework. The United Nations has stated that digital technologies have advanced at a rate that surpasses any innovation in history, affecting approximately 50% of the population of the developing world in a mere two decades and dramatically altering societies. Thus, the increasing digital transformation across healthcare verticals supports the market's growth.

Market Restraining Factors

These 4.0 calls for an extensive modernization of existing manufacturing infrastructure, which includes replacing outdated machinery with cutting-edge equipment, such as IoT-enabled devices, automation systems, and robotics. Additionally, companies must invest in advanced software solutions like artificial intelligence (AI) and machine learning (ML) platforms to enable predictive analytics, quality control, and data integration. Hence, the combination of high upfront capital and ongoing costs creates a significant obstacle to the widespread adoption of these 4.0 solutions, slowing the market's overall growth trajectory.

Type Outlook

Based on type, this market is bifurcated into software and services. The services segment procured 45% revenue share in this 4.0 market in 2023. This segment includes various support services, including implementation, consulting, training, and maintenance. As pharmaceutical companies adopt new digital tools and technologies, they rely on specialized services to ensure smooth integration, effective utilization, and long-term maintenance of these systems.

Application Outlook

By application, this market is divided into drug discovery & development, manufacturing, supply chain management, and others. The supply chain management segment garnered 22% revenue share in this 4.0 market in 2023. Integrating digital technologies, such as blockchain, IoT, and advanced analytics, has revolutionized the pharmaceutical supply chain, providing greater transparency, security, and efficiency.

End Use Outlook

Based on end use, this market is segmented into pharma & biotech companies, healthcare providers, and CRO & CDMO. The CRO & CDMO segment acquired 33% revenue share in this 4.0 market in 2023. The CRO (Contract Research Organizations) & CDMO (Contract Development and Manufacturing Organizations) play a pivotal role in supporting pharmaceutical and biotech companies by offering outsourced research, development, and manufacturing services.

Technology Outlook

On the basis of technology, this market is classified into AI & ML, big data analytics, IoT, blockchain technology, and others. The blockchain technology segment recorded 9% revenue share in this 4.0 market in 2023. Blockchain's ability to provide secure, transparent, and immutable records has made it a valuable tool for ensuring drug safety and compliance in the pharmaceutical industry.

Regional Outlook

Region-wise, this market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Europe segment witnessed 29% revenue share in this 4.0 market in 2023. Countries like Germany, the United Kingdom, and Switzerland are key players in adopting Pharma 4.0 technologies, focusing on improving the efficiency of drug manufacturing, regulatory compliance, and supply chain management.

Recent Strategies Deployed in the Market

• Mar-2024: IBM Corporation took over Pliant, a network and IT infrastructure automation company. The acquisition enhances IBM's software portfolio, including SevOne and Cloud Pak for Network Automation.
• Jan-2024: Amazon Web Services, Inc. partnered with Siemens, a global technology company, to integrate Bedrock with Siemens' Mendix low-code platform, enabling businesses to easily build generative AI applications. This partnership simplifies development, boosts productivity, and democratizes AI technology, allowing users without programming expertise to create advanced applications across industries, enhancing innovation and efficiency.
• Dec-2023: Siemens Healthineers AG teamed up with Cognosos, an asset-tracking technology company, to launch a real-time location system (RTLS) using Bluetooth Low Energy (BLE) and AI to track mobile assets in healthcare facilities. The solution enhances asset management, reduces costs, and improves efficiency with easy deployment and room-level accuracy.
• Nov-2023: Amazon Web Services, Inc. came into partnership with Merck, a global biotechnology company, to accelerate drug discovery using generative AI. The partnership would boost drug discovery and manufacturing efficiency through AI and machine learning.
• Sep-2023: SAP plans acquired LeanIX, an enterprise architecture management software leader. The acquisition would enhance SAP's capabilities in AI-enabled process optimization and provide customers with a comprehensive view of IT landscapes, supporting continuous transformation and modernization in a rapidly changing business environment.

List of Key Companies Profiled

• Amazon Web Services, Inc.
• SAP SE
• Oracle Corporation
• Microsoft Corporation
• IBM Corporation
• GE HealthCare Technologies, Inc.
• Siemens Healthineers AG (Siemens AG)
• Cisco Systems, Inc.
• Dassault Systemes SE
• UnitedHealth Group, Inc. (Optum, Inc.)

Global Pharma 4.0 Market Report Segmentation

By Type

• Software
• Services

By Application

• Drug Discovery & Development
• Manufacturing
• Supply Chain Management
• Other Application

By End Use

• Pharma & Biotech companies
• CRO & CDMO
• Healthcare Providers

By Technology

• AI & ML
• Big Data Analytics
• IoT
• Blockchain Technology
• Other Technology

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
• Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Pharma 4.0 Market, by Type
  • 1.4.2 Global Pharma 4.0 Market, by Application
  • 1.4.3 Global Pharma 4.0 Market, by End Use
  • 1.4.4 Global Pharma 4.0 Market, by Technology
  • 1.4.5 Global Pharma 4.0 Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges

Chapter 4. Competition Analysis - Global

• 4.1 KBV Cardinal Matrix
• 4.2 Recent Industry Wide Strategic Developments
  • 4.2.1 Partnerships, Collaborations and Agreements
  • 4.2.2 Product Launches and Product Expansions
  • 4.2.3 Acquisition and Mergers
• 4.3 Market Share Analysis, 2023
• 4.4 Top Winning Strategies
  • 4.4.1 Key Leading Strategies: Percentage Distribution (2020-2024)
  • 4.4.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2023, May - 2024, Sep) Leading Players
• 4.5 Porter Five Forces Analysis

Chapter 5. Global Pharma 4.0 Market by Type

• 5.1 Global Software Market by Region
• 5.2 Global Services Market by Region

Chapter 6. Global Pharma 4.0 Market by Application

• 6.1 Global Drug Discovery & Development Market by Region
• 6.2 Global Manufacturing Market by Region
• 6.3 Global Supply Chain Management Market by Region
• 6.4 Global Other Application Market by Region

Chapter 7. Global Pharma 4.0 Market by End Use

• 7.1 Global Pharma & Biotech companies Market by Region
• 7.2 Global CRO & CDMO Market by Region
• 7.3 Global Healthcare Providers Market by Region

Chapter 8. Global Pharma 4.0 Market by Technology

• 8.1 Global AI & ML Market by Region
• 8.2 Global Big Data Analytics Market by Region
• 8.3 Global IoT Market by Region
• 8.4 Global Blockchain Technology Market by Region
• 8.5 Global Other Technology Market by Region

Chapter 9. Global Pharma 4.0 Market by Region

• 9.1 North America Pharma 4.0 Market
  • 9.1.1 North America Pharma 4.0 Market by Type
    • 9.1.1.1 North America Software Market by Region
    • 9.1.1.2 North America Services Market by Region
  • 9.1.2 North America Pharma 4.0 Market by Application
    • 9.1.2.1 North America Drug Discovery & Development Market by Country
    • 9.1.2.2 North America Manufacturing Market by Country
    • 9.1.2.3 North America Supply Chain Management Market by Country
    • 9.1.2.4 North America Other Application Market by Country
  • 9.1.3 North America Pharma 4.0 Market by End Use
    • 9.1.3.1 North America Pharma & Biotech companies Market by Country
    • 9.1.3.2 North America CRO & CDMO Market by Country
    • 9.1.3.3 North America Healthcare Providers Market by Country
  • 9.1.4 North America Pharma 4.0 Market by Technology
    • 9.1.4.1 North America AI & ML Market by Country
    • 9.1.4.2 North America Big Data Analytics Market by Country
    • 9.1.4.3 North America IoT Market by Country
    • 9.1.4.4 North America Blockchain Technology Market by Country
    • 9.1.4.5 North America Other Technology Market by Country
  • 9.1.5 North America Pharma 4.0 Market by Country
    • 9.1.5.1 US Pharma 4.0 Market
      • 9.1.5.1.1 US Pharma 4.0 Market by Type
      • 9.1.5.1.2 US Pharma 4.0 Market by Application
      • 9.1.5.1.3 US Pharma 4.0 Market by End Use
      • 9.1.5.1.4 US Pharma 4.0 Market by Technology
    • 9.1.5.2 Canada Pharma 4.0 Market
      • 9.1.5.2.1 Canada Pharma 4.0 Market by Type
      • 9.1.5.2.2 Canada Pharma 4.0 Market by Application
      • 9.1.5.2.3 Canada Pharma 4.0 Market by End Use
      • 9.1.5.2.4 Canada Pharma 4.0 Market by Technology
    • 9.1.5.3 Mexico Pharma 4.0 Market
      • 9.1.5.3.1 Mexico Pharma 4.0 Market by Type
      • 9.1.5.3.2 Mexico Pharma 4.0 Market by Application
      • 9.1.5.3.3 Mexico Pharma 4.0 Market by End Use
      • 9.1.5.3.4 Mexico Pharma 4.0 Market by Technology
    • 9.1.5.4 Rest of North America Pharma 4.0 Market
      • 9.1.5.4.1 Rest of North America Pharma 4.0 Market by Type
      • 9.1.5.4.2 Rest of North America Pharma 4.0 Market by Application
      • 9.1.5.4.3 Rest of North America Pharma 4.0 Market by End Use
      • 9.1.5.4.4 Rest of North America Pharma 4.0 Market by Technology
• 9.2 Europe Pharma 4.0 Market
  • 9.2.1 Europe Pharma 4.0 Market by Type
    • 9.2.1.1 Europe Software Market by Country
    • 9.2.1.2 Europe Services Market by Country
  • 9.2.2 Europe Pharma 4.0 Market by Application
    • 9.2.2.1 Europe Drug Discovery & Development Market by Country
    • 9.2.2.2 Europe Manufacturing Market by Country
    • 9.2.2.3 Europe Supply Chain Management Market by Country
    • 9.2.2.4 Europe Other Application Market by Country
  • 9.2.3 Europe Pharma 4.0 Market by End Use
    • 9.2.3.1 Europe Pharma & Biotech companies Market by Country
    • 9.2.3.2 Europe CRO & CDMO Market by Country
    • 9.2.3.3 Europe Healthcare Providers Market by Country
  • 9.2.4 Europe Pharma 4.0 Market by Technology
    • 9.2.4.1 Europe AI & ML Market by Country
    • 9.2.4.2 Europe Big Data Analytics Market by Country
    • 9.2.4.3 Europe IoT Market by Country
    • 9.2.4.4 Europe Blockchain Technology Market by Country
    • 9.2.4.5 Europe Other Technology Market by Country
  • 9.2.5 Europe Pharma 4.0 Market by Country
    • 9.2.5.1 Germany Pharma 4.0 Market
      • 9.2.5.1.1 Germany Pharma 4.0 Market by Type
      • 9.2.5.1.2 Germany Pharma 4.0 Market by Application
      • 9.2.5.1.3 Germany Pharma 4.0 Market by End Use
      • 9.2.5.1.4 Germany Pharma 4.0 Market by Technology
    • 9.2.5.2 UK Pharma 4.0 Market
      • 9.2.5.2.1 UK Pharma 4.0 Market by Type
      • 9.2.5.2.2 UK Pharma 4.0 Market by Application
      • 9.2.5.2.3 UK Pharma 4.0 Market by End Use
      • 9.2.5.2.4 UK Pharma 4.0 Market by Technology
    • 9.2.5.3 France Pharma 4.0 Market
      • 9.2.5.3.1 France Pharma 4.0 Market by Type
      • 9.2.5.3.2 France Pharma 4.0 Market by Application
      • 9.2.5.3.3 France Pharma 4.0 Market by End Use
      • 9.2.5.3.4 France Pharma 4.0 Market by Technology
    • 9.2.5.4 Russia Pharma 4.0 Market
      • 9.2.5.4.1 Russia Pharma 4.0 Market by Type
      • 9.2.5.4.2 Russia Pharma 4.0 Market by Application
      • 9.2.5.4.3 Russia Pharma 4.0 Market by End Use
      • 9.2.5.4.4 Russia Pharma 4.0 Market by Technology
    • 9.2.5.5 Spain Pharma 4.0 Market
      • 9.2.5.5.1 Spain Pharma 4.0 Market by Type
      • 9.2.5.5.2 Spain Pharma 4.0 Market by Application
      • 9.2.5.5.3 Spain Pharma 4.0 Market by End Use
      • 9.2.5.5.4 Spain Pharma 4.0 Market by Technology
    • 9.2.5.6 Italy Pharma 4.0 Market
      • 9.2.5.6.1 Italy Pharma 4.0 Market by Type
      • 9.2.5.6.2 Italy Pharma 4.0 Market by Application
      • 9.2.5.6.3 Italy Pharma 4.0 Market by End Use
      • 9.2.5.6.4 Italy Pharma 4.0 Market by Technology
    • 9.2.5.7 Rest of Europe Pharma 4.0 Market
      • 9.2.5.7.1 Rest of Europe Pharma 4.0 Market by Type
      • 9.2.5.7.2 Rest of Europe Pharma 4.0 Market by Application
      • 9.2.5.7.3 Rest of Europe Pharma 4.0 Market by End Use
      • 9.2.5.7.4 Rest of Europe Pharma 4.0 Market by Technology
• 9.3 Asia Pacific Pharma 4.0 Market
  • 9.3.1 Asia Pacific Pharma 4.0 Market by Type
    • 9.3.1.1 Asia Pacific Software Market by Country
    • 9.3.1.2 Asia Pacific Services Market by Country
  • 9.3.2 Asia Pacific Pharma 4.0 Market by Application
    • 9.3.2.1 Asia Pacific Drug Discovery & Development Market by Country
    • 9.3.2.2 Asia Pacific Manufacturing Market by Country
    • 9.3.2.3 Asia Pacific Supply Chain Management Market by Country
    • 9.3.2.4 Asia Pacific Other Application Market by Country
  • 9.3.3 Asia Pacific Pharma 4.0 Market by End Use
    • 9.3.3.1 Asia Pacific Pharma & Biotech companies Market by Country
    • 9.3.3.2 Asia Pacific CRO & CDMO Market by Country
    • 9.3.3.3 Asia Pacific Healthcare Providers Market by Country
  • 9.3.4 Asia Pacific Pharma 4.0 Market by Technology
    • 9.3.4.1 Asia Pacific AI & ML Market by Country
    • 9.3.4.2 Asia Pacific Big Data Analytics Market by Country
    • 9.3.4.3 Asia Pacific IoT Market by Country
    • 9.3.4.4 Asia Pacific Blockchain Technology Market by Country
    • 9.3.4.5 Asia Pacific Other Technology Market by Country
  • 9.3.5 Asia Pacific Pharma 4.0 Market by Country
    • 9.3.5.1 China Pharma 4.0 Market
      • 9.3.5.1.1 China Pharma 4.0 Market by Type
      • 9.3.5.1.2 China Pharma 4.0 Market by Application
      • 9.3.5.1.3 China Pharma 4.0 Market by End Use
      • 9.3.5.1.4 China Pharma 4.0 Market by Technology
    • 9.3.5.2 Japan Pharma 4.0 Market
      • 9.3.5.2.1 Japan Pharma 4.0 Market by Type
      • 9.3.5.2.2 Japan Pharma 4.0 Market by Application
      • 9.3.5.2.3 Japan Pharma 4.0 Market by End Use
      • 9.3.5.2.4 Japan Pharma 4.0 Market by Technology
    • 9.3.5.3 India Pharma 4.0 Market
      • 9.3.5.3.1 India Pharma 4.0 Market by Type
      • 9.3.5.3.2 India Pharma 4.0 Market by Application
      • 9.3.5.3.3 India Pharma 4.0 Market by End Use
      • 9.3.5.3.4 India Pharma 4.0 Market by Technology
    • 9.3.5.4 South Korea Pharma 4.0 Market
      • 9.3.5.4.1 South Korea Pharma 4.0 Market by Type
      • 9.3.5.4.2 South Korea Pharma 4.0 Market by Application
      • 9.3.5.4.3 South Korea Pharma 4.0 Market by End Use
      • 9.3.5.4.4 South Korea Pharma 4.0 Market by Technology
    • 9.3.5.5 Singapore Pharma 4.0 Market
      • 9.3.5.5.1 Singapore Pharma 4.0 Market by Type
      • 9.3.5.5.2 Singapore Pharma 4.0 Market by Application
      • 9.3.5.5.3 Singapore Pharma 4.0 Market by End Use
      • 9.3.5.5.4 Singapore Pharma 4.0 Market by Technology
    • 9.3.5.6 Malaysia Pharma 4.0 Market
      • 9.3.5.6.1 Malaysia Pharma 4.0 Market by Type
      • 9.3.5.6.2 Malaysia Pharma 4.0 Market by Application
      • 9.3.5.6.3 Malaysia Pharma 4.0 Market by End Use
      • 9.3.5.6.4 Malaysia Pharma 4.0 Market by Technology
    • 9.3.5.7 Rest of Asia Pacific Pharma 4.0 Market
      • 9.3.5.7.1 Rest of Asia Pacific Pharma 4.0 Market by Type
      • 9.3.5.7.2 Rest of Asia Pacific Pharma 4.0 Market by Application
      • 9.3.5.7.3 Rest of Asia Pacific Pharma 4.0 Market by End Use
      • 9.3.5.7.4 Rest of Asia Pacific Pharma 4.0 Market by Technology
• 9.4 LAMEA Pharma 4.0 Market
  • 9.4.1 LAMEA Pharma 4.0 Market by Type
    • 9.4.1.1 LAMEA Software Market by Country
    • 9.4.1.2 LAMEA Services Market by Country
  • 9.4.2 LAMEA Pharma 4.0 Market by Application
    • 9.4.2.1 LAMEA Drug Discovery & Development Market by Country
    • 9.4.2.2 LAMEA Manufacturing Market by Country
    • 9.4.2.3 LAMEA Supply Chain Management Market by Country
    • 9.4.2.4 LAMEA Other Application Market by Country
  • 9.4.3 LAMEA Pharma 4.0 Market by End Use
    • 9.4.3.1 LAMEA Pharma & Biotech companies Market by Country
    • 9.4.3.2 LAMEA CRO & CDMO Market by Country
    • 9.4.3.3 LAMEA Healthcare Providers Market by Country
  • 9.4.4 LAMEA Pharma 4.0 Market by Technology
    • 9.4.4.1 LAMEA AI & ML Market by Country
    • 9.4.4.2 LAMEA Big Data Analytics Market by Country
    • 9.4.4.3 LAMEA IoT Market by Country
    • 9.4.4.4 LAMEA Blockchain Technology Market by Country
    • 9.4.4.5 LAMEA Other Technology Market by Country
  • 9.4.5 LAMEA Pharma 4.0 Market by Country
    • 9.4.5.1 Brazil Pharma 4.0 Market
      • 9.4.5.1.1 Brazil Pharma 4.0 Market by Type
      • 9.4.5.1.2 Brazil Pharma 4.0 Market by Application
      • 9.4.5.1.3 Brazil Pharma 4.0 Market by End Use
      • 9.4.5.1.4 Brazil Pharma 4.0 Market by Technology
    • 9.4.5.2 Argentina Pharma 4.0 Market
      • 9.4.5.2.1 Argentina Pharma 4.0 Market by Type
      • 9.4.5.2.2 Argentina Pharma 4.0 Market by Application
      • 9.4.5.2.3 Argentina Pharma 4.0 Market by End Use
      • 9.4.5.2.4 Argentina Pharma 4.0 Market by Technology
    • 9.4.5.3 UAE Pharma 4.0 Market
      • 9.4.5.3.1 UAE Pharma 4.0 Market by Type
      • 9.4.5.3.2 UAE Pharma 4.0 Market by Application
      • 9.4.5.3.3 UAE Pharma 4.0 Market by End Use
      • 9.4.5.3.4 UAE Pharma 4.0 Market by Technology
    • 9.4.5.4 Saudi Arabia Pharma 4.0 Market
      • 9.4.5.4.1 Saudi Arabia Pharma 4.0 Market by Type
      • 9.4.5.4.2 Saudi Arabia Pharma 4.0 Market by Application
      • 9.4.5.4.3 Saudi Arabia Pharma 4.0 Market by End Use
      • 9.4.5.4.4 Saudi Arabia Pharma 4.0 Market by Technology
    • 9.4.5.5 South Africa Pharma 4.0 Market
      • 9.4.5.5.1 South Africa Pharma 4.0 Market by Type
      • 9.4.5.5.2 South Africa Pharma 4.0 Market by Application
      • 9.4.5.5.3 South Africa Pharma 4.0 Market by End Use
      • 9.4.5.5.4 South Africa Pharma 4.0 Market by Technology
    • 9.4.5.6 Nigeria Pharma 4.0 Market
      • 9.4.5.6.1 Nigeria Pharma 4.0 Market by Type
      • 9.4.5.6.2 Nigeria Pharma 4.0 Market by Application
      • 9.4.5.6.3 Nigeria Pharma 4.0 Market by End Use
      • 9.4.5.6.4 Nigeria Pharma 4.0 Market by Technology
    • 9.4.5.7 Rest of LAMEA Pharma 4.0 Market
      • 9.4.5.7.1 Rest of LAMEA Pharma 4.0 Market by Type
      • 9.4.5.7.2 Rest of LAMEA Pharma 4.0 Market by Application
      • 9.4.5.7.3 Rest of LAMEA Pharma 4.0 Market by End Use
      • 9.4.5.7.4 Rest of LAMEA Pharma 4.0 Market by Technology

Chapter 10. Company Profiles

• 10.1 Amazon Web Services, Inc. (Amazon.com, Inc.)
  • 10.1.1 Company Overview
  • 10.1.2 Financial Analysis
  • 10.1.3 Segmental Analysis
  • 10.1.4 Recent strategies and developments:
    • 10.1.4.1 Partnerships, Collaborations, and Agreements:
  • 10.1.5 SWOT Analysis
• 10.2 Oracle Corporation
  • 10.2.1 Company Overview
  • 10.2.2 Financial Analysis
  • 10.2.3 Segmental and Regional Analysis
  • 10.2.4 Research & Development Expense
  • 10.2.5 Recent strategies and developments:
    • 10.2.5.1 Partnerships, Collaborations, and Agreements:
    • 10.2.5.2 Acquisition and Mergers:
  • 10.2.6 SWOT Analysis
• 10.3 Microsoft Corporation
  • 10.3.1 Company Overview
  • 10.3.2 Financial Analysis
  • 10.3.3 Segmental and Regional Analysis
  • 10.3.4 Research & Development Expenses
  • 10.3.5 Recent strategies and developments:
    • 10.3.5.1 Product Launches and Product Expansions:
  • 10.3.6 SWOT Analysis
• 10.4 IBM Corporation
  • 10.4.1 Company Overview
  • 10.4.2 Financial Analysis
  • 10.4.3 Regional & Segmental Analysis
  • 10.4.4 Research & Development Expenses
  • 10.4.5 Recent strategies and developments:
    • 10.4.5.1 Partnerships, Collaborations, and Agreements:
    • 10.4.5.2 Acquisition and Mergers:
  • 10.4.6 SWOT Analysis
• 10.5 SAP SE
  • 10.5.1 Company Overview
  • 10.5.2 Financial Analysis
  • 10.5.3 Regional Analysis
  • 10.5.4 Research & Development Expense
  • 10.5.5 Recent strategies and developments:
    • 10.5.5.1 Partnerships, Collaborations, and Agreements:
    • 10.5.5.2 Acquisition and Mergers:
  • 10.5.6 SWOT Analysis
• 10.6 GE HealthCare Technologies, Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Financial Analysis
  • 10.6.3 Segmental and Regional Analysis
  • 10.6.4 Research & Development Expenses
  • 10.6.5 Recent strategies and developments:
    • 10.6.5.1 Product Launches and Product Expansions:
  • 10.6.6 SWOT Analysis
• 10.7 Siemens Healthineers AG (Siemens AG)
  • 10.7.1 Company Overview
  • 10.7.2 Financial Analysis
  • 10.7.3 Segmental and Regional Analysis
  • 10.7.4 Research & Development Expense
  • 10.7.5 Recent strategies and developments:
    • 10.7.5.1 Partnerships, Collaborations, and Agreements:
  • 10.7.6 SWOT Analysis
• 10.8 Cisco Systems, Inc.
  • 10.8.1 Company Overview
  • 10.8.2 Financial Analysis
  • 10.8.3 Regional Analysis
  • 10.8.4 Research & Development Expense
  • 10.8.5 Recent strategies and developments:
    • 10.8.5.1 Partnerships, Collaborations, and Agreements:
  • 10.8.6 SWOT Analysis
• 10.9 Dassault Systemes SE
  • 10.9.1 Company Overview
  • 10.9.2 Financial Analysis
  • 10.9.3 Regional Analysis
  • 10.9.4 Research & Development Expense
  • 10.9.5 Recent strategies and developments:
    • 10.9.5.1 Partnerships, Collaborations, and Agreements:
  • 10.9.6 SWOT Analysis
• 10.10. UnitedHealth Group, Inc. (Optum, Inc.)
  • 10.10.1 Company Overview
  • 10.10.2 Financial Analysis
  • 10.10.3 Segmental Analysis

Chapter 11. Winning Imperatives for Pharma 4.0 Market